Sarepta Therapeutics 관리
관리 기준 확인 4/4
Sarepta Therapeutics CEO는 Doug Ingram, Jun2017 에 임명되었습니다 의 임기는 7.42 년입니다. 총 연간 보상은 $ 1.66M, 48.1% 로 구성됩니다. 48.1% 급여 및 51.9% 보너스(회사 주식 및 옵션 포함). 는 $ 43.13M 가치에 해당하는 회사 주식의 0.41% 직접 소유합니다. 43.13M. 경영진과 이사회의 평균 재임 기간은 각각 3.9 년과 8.5 년입니다.
주요 정보
Doug Ingram
최고 경영자
US$1.7m
총 보상
| CEO 급여 비율 | 48.1% |
| CEO 임기 | 7.4yrs |
| CEO 소유권 | 0.4% |
| 경영진 평균 재임 기간 | 3.9yrs |
| 이사회 평균 재임 기간 | 8.5yrs |
최근 관리 업데이트
Recent updates
Sarepta Therapeutics (NASDAQ:SRPT) Is Posting Healthy Earnings, But It Is Not All Good News
Nov 13
Is Sarepta Therapeutics (NASDAQ:SRPT) A Risky Investment?
Oct 20The Play On Sarepta Therapeutics
Sep 26Sarepta Therapeutics Muscles Up In DMD Race
Sep 19Sarepta Therapeutics' Pullback After Recent FDA Approval A Buying Opportunity
Jul 24Revenues Not Telling The Story For Sarepta Therapeutics, Inc. (NASDAQ:SRPT) After Shares Rise 28%
Jul 05Sarepta Therapeutics: Navigating Elevidys Upside Potential
Jun 17Sarepta Therapeutics' (NASDAQ:SRPT) Earnings Aren't As Good As They Appear
May 08Results: Sarepta Therapeutics, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
May 05Is Sarepta Therapeutics (NASDAQ:SRPT) Using Debt In A Risky Way?
Apr 15Sarepta Therapeutics: Growth Trajectory Alters Trading Strategy
Apr 11Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Mar 02Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Fly 29% But Investors Aren't Buying For Growth
Feb 06Sarepta Therapeutics: Navigating Elevidys Towards FDA Approval
Jan 22Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Could Be 50% Below Their Intrinsic Value Estimate
Jan 10There's No Escaping Sarepta Therapeutics, Inc.'s (NASDAQ:SRPT) Muted Revenues
Dec 20Does Sarepta Therapeutics (NASDAQ:SRPT) Have A Healthy Balance Sheet?
Nov 29Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Aug 08Is Sarepta Therapeutics (NASDAQ:SRPT) Using Too Much Debt?
Apr 30Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Jan 17Sarepta Therapeutics seeks FDA accelerated approval for muscle wasting therapy SRP-9001
Sep 29Sarepta Therapeutics announces offering of $1B of convertible senior notes due 2027
Sep 12Sarepta says FDA lifted clinical hold on Duchenne candidate
Sep 06Is Sarepta Therapeutics (NASDAQ:SRPT) Weighed On By Its Debt Load?
Aug 22Sarepta inks licensing deal with Broad Institute for certain adeno-associated viruses
Aug 08Sarepta stock soars 19% on plans for US filing for gene therapy for neuromuscular disorder
Jul 29CEO 보상 분석
| 날짜 | 총 보상 | 급여 | 회사 수익 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$122m |
| Jun 30 2024 | n/a | n/a | US$47m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$2m | US$800k | -US$536m |
| Sep 30 2023 | n/a | n/a | -US$691m |
| Jun 30 2023 | n/a | n/a | -US$908m |
| Mar 31 2023 | n/a | n/a | -US$1b |
| Dec 31 2022 | US$125m | US$740k | -US$703m |
| Sep 30 2022 | n/a | n/a | -US$716m |
| Jun 30 2022 | n/a | n/a | -US$507m |
| Mar 31 2022 | n/a | n/a | -US$357m |
| Dec 31 2021 | US$2m | US$730k | -US$419m |
| Sep 30 2021 | n/a | n/a | -US$486m |
| Jun 30 2021 | n/a | n/a | -US$634m |
| Mar 31 2021 | n/a | n/a | -US$704m |
| Dec 31 2020 | US$1m | US$669k | -US$554m |
| Sep 30 2020 | n/a | n/a | -US$601m |
| Jun 30 2020 | n/a | n/a | -US$530m |
| Mar 31 2020 | n/a | n/a | -US$656m |
| Dec 31 2019 | US$1m | US$650k | -US$715m |
| Sep 30 2019 | n/a | n/a | -US$620m |
| Jun 30 2019 | n/a | n/a | -US$570m |
| Mar 31 2019 | n/a | n/a | -US$403m |
| Dec 31 2018 | US$1m | US$650k | -US$362m |
| Sep 30 2018 | n/a | n/a | -US$245m |
| Jun 30 2018 | n/a | n/a | -US$216m |
| Mar 31 2018 | n/a | n/a | -US$170m |
| Dec 31 2017 | US$57m | US$338k | -US$51m |
보상 대 시장: Doug 의 총 보상 ($USD 1.66M ) US 시장에서 비슷한 규모의 회사에 대한 평균보다 낮습니다( $USD 12.67M ).
보상과 수익: Doug 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.
CEO
Doug Ingram (61 yo)
7.4yrs
테뉴어
US$1,661,338
보상
Mr. Douglas S. Ingram, also known as Doug, J.D., Esq., has been Chief Executive Officer and President of Sarepta Therapeutics, Inc. since June 26, 2017. Mr. Ingram serves as an Independent Director of Rela...
리더십 팀
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 7.4yrs | US$1.66m | 0.41% $ 43.1m | |
| Executive VP & CFO | 3.9yrs | US$3.71m | 0.036% $ 3.8m | |
| Executive VP & Chief Technical Operations Officer | 1.9yrs | US$3.52m | 0.018% $ 1.9m | |
| Executive VP | 3.9yrs | US$3.72m | 0.076% $ 8.0m | |
| Executive VP | 3.9yrs | US$3.58m | 0.018% $ 1.9m | |
| Executive Director of Investor Relations and Corporate Communications | no data | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief People Officer | 3.1yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP and Chief of Global Policy & Advocacy Officer | 5.2yrs | 데이터 없음 | 데이터 없음 | |
| Executive VP & Chief Customer Officer | 3.9yrs | 데이터 없음 | 0.023% $ 2.4m | |
| Senior VP | 1.8yrs | 데이터 없음 | 데이터 없음 | |
| Controller & VP | 7.7yrs | US$911.89k | 데이터 없음 | |
| Senior Manager of Investor Relations | no data | 데이터 없음 | 데이터 없음 |
3.9yrs
평균 재임 기간
50yo
평균 연령
경험이 풍부한 관리: SRPT 의 관리팀은 경험 ( 3.9 년 평균 재직 기간)으로 간주됩니다.
이사회 구성원
| 이름 | 위치 | 테뉴어 | 보상 | 소유권 |
|---|---|---|---|---|
| President | 7.4yrs | US$1.66m | 0.41% $ 43.1m | |
| Independent Chairwoman | 15.7yrs | US$594.99k | 0.21% $ 22.0m | |
| Chairman of Corporate Strategy Board & Independent Non-Employee Director | 14.4yrs | US$546.99k | 0.022% $ 2.3m | |
| Independent Director | 9.4yrs | US$563.65k | 3.33% $ 351.4m | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 5yrs | 데이터 없음 | 데이터 없음 | |
| Member of Strategic & Scientific Advisory Board | 9.3yrs | 데이터 없음 | 데이터 없음 | |
| Independent Non-Employee Director | 9.4yrs | US$553.34k | 0.017% $ 1.8m | |
| Member of Strategic & Scientific Advisory Board | 7.7yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 4.9yrs | 데이터 없음 | 데이터 없음 | |
| Member of Strategic & Scientific Advisory Board | 7.7yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 5yrs | 데이터 없음 | 데이터 없음 |
8.5yrs
평균 재임 기간
71yo
평균 연령
경험이 풍부한 이사회: SRPT 의 이사회는 경험(평균 재직 기간 8.5 년)으로 간주됩니다.